

United States Patent and Trademark Office

S DEPARTMENT OF COMMERCE tent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/748,708	12/31/2003	Stephan Brunner	1866.0360004/PEG/CMB	2143
26111	7590 06/19/2006		EXAMINER	
STERNE, KESSLER, GOLDSTEIN & FOX PLLC			SKIBINSKY, ANNA	
	1100 NEW YORK AVENUE, N.W. WASHINGTON, DC 20005		ART UNIT	PAPER NUMBER
			1631	<u> </u>
			DATE MAILED: 06/19/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/748,708	BRUNNER ET AL.				
Office Action Summary	Examiner	Art Unit				
	Anna Skibinsky	1631				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin vill apply and will expire SIX (6) MONTHS from to cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status		:				
1) Responsive to communication(s) filed on 31 De	ecember 2003.					
,	action is non-final.	<u>:</u>				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims		<u>:</u>				
4) ☑ Claim(s) 1-11 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☑ Claim(s) 1-11 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	wn from consideration.					
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acce Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex	epted or b) objected to by the liderawing(s) be held in abeyance. Section is required if the drawing(s) is object.	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some col None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)						
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 	Paper No(s)/Mail D					

Application/Control Number: 10/748,708

Art Unit: 1631

DETAILED ACTION

Objection to the Specification

The abstract of the disclosure is objected to because it is over 150 words long. Correction is required. See MPEP § 608.01(b).

Claim Rejections - 35 USC § 101

Claims 1-11 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.

Said claims are toward a computer implemented algorithm for identifying drug leads using Grand-Canonical Metropolis Monte Carlo simulations. Though the properties calculated by the model are physical properties, the data is nontheless generated within a computer without a physical manifestation. The independent claims lack a physical step such as a visual display of results, memory in communication with a processor, physical inputting of data, or collection of a physical sample. Thus, these claims do not produce a result which meet the standard of being concrete, tangible and useful.

The claims "must be for a practical application of the abstract idea, law of nature, or natural phenomenon. Diehr, 450 U.S. at 187, 209 USPQ at 8 ("application of a law of nature or mathematical formula to a known structure or process may well be deserving of patent protection."); Benson, 409 U.S. at 71, 175 USPQ at 676 (rejecting formula claim because it "has no substantial practical application").

Application/Control Number: 10/748,708

Art Unit: 1631

To satisfy section 101 requirements, the claim must be for a practical application of the § 101 judicial exception, which can be identified in various ways:

- 1) The claimed invention "transforms" an article or physical object to a different state or thing.
- 2) The claimed invention otherwise produces a useful, concrete and tangible result, based on the factors discussed in MPEP 2106, and See also:

 http://www.uspto.gov/web/offices/pac/dapp/opla/preognotice/guidelines101_20051026.pdf

The manipulation of coordinates and interaction energies or residues to calculate the crossover point is the manipulation of numbers, performed by the computer implementing programs and is therefore nonstatutory subject matter. Manipulation of data does not include a physical transformation outside of a computer or representation thereof. A process consisting solely of mathematical operations, i.e., converting one set of numbers into another set of numbers, does not manipulate appropriate subject matter and is not deemed to be concrete, tangible, and useful and is therefore non-statutory. An example which would make the instant method steps statutory would be to include a step of displaying the data for a user. Hence, the data would become concrete, tangible, and useful.

Claim Rejections - 35 USC § 112

1. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Application/Control Number: 10/748,708

Art Unit: 1631

2. Claims 1-11 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

- 3. The equation of claims 1, 11, and 11 recites a "- $B_{num}(Y_j)$ " in the exponential. However, a definition for " Y_j " is not provided. In the specification (page 8, paragraph 0029), " Y_i " is defined, where "i" is the fragment, however " Y_j " is not defined. Clarification is requested.
- The equation of claims 1 and 11 recite $B_{num}(x_i)$ where " x_i " indicates the position as defined in the specification (paragraph 0029). It is unclear if "fixing the field $B_{num}(x)$ " refers to when only " $B_{num}(x_i)$ " is defined. Clarification is requested.
- 5. Claims 1, 6, and 11 recite "outputting samples" or "output sample" from the equilibration Markov chain. It is unclear where the output takes place and if it is onto a visual display such as a computer screen.
- 6. Claims 1, 6, and 11 recite "outputting samples" or "output sample" from the equilibration Markov chain. It is unclear where the output takes place and if it is onto a visual display such as a computer screen. It is unclear what said samples are and if these are the samples of protein fragments.
- 7. Claims 1, 6, and 11 recite that the method is for "identifying drug leads" however there is no such identifying step in the claims. The last line of claims 1, 6 and 11 recite the outputting of samples but it is not clear if these samples are the drug leads.

 Clarification is requested.

Application/Control Number: 10/748,708 Page 5

Art Unit: 1631

Double Patenting

8. A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer <u>cannot</u> overcome a double patenting rejection based upon 35 U.S.C. 101.

9. Claims 1-11 are provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-11 of copending Application No. 10/794181. This is a provisional double patenting rejection since the conflicting claims have not in fact been patented.

The subject matter claimed in the instant application is fully disclosed in the referenced copending application and would be covered by any patent granted on that copending application since the referenced copending application and the instant application are claiming common subject matter, as follows: The claims in application 10/794181 are identical to those in the instant application. Both applications are to a method for modeling a system using Grand-Canonical Metropolis Monte Carlo to

Application/Control Number: 10/748,708 Page 6

Art Unit: 1631

identify drug target leads. The equation in the independent claims defining the weighted number of sampled fragments is identical in both applications.

This is a provisional obviousness-type double patenting rejection.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anna Skibinsky whose telephone number is (571) 272-4373. The examiner can normally be reached on 8 am - 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on (571) 272-0811. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

ANDREW WANG
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600